Sanne Bootsma, Mark P G Dings, Job Kesselaar, Roxan F C P A Helderman, Kyah van Megesen, Alexander Constantinides, Leandro Ferreira Moreno, Ellen Stelloo, Enzo M Scutigliani, Bella Bokan, Arezo Torang, Sander R van Hooff, Danny A Zwijnenburg, Valérie M Wouters, Vincent C J van de Vlasakker, Laskarina J K Galanos, Lisanne E Nijman, Adrian Logiantara, Veronique L Veenstra, Sophie Schlingemann, Sterre van Piggelen, Nicole van der Wel, Przemek M Krawczyk, Johannes J Platteeuw, Jurriaan B Tuynman, Ignace H de Hingh, Jan P G Klomp, Arthur Oubrie, Petur Snaebjornsson, Jan Paul Medema, Arlene L Oei, Onno Kranenburg, Clara C Elbers, Kristiaan J Lenos, Louis Vermeulen, Maarten F Bijlsma
Peritoneal metastases (PMs) from colorectal cancer (CRC) respond poorly to treatment and are associated with unfavorable prognosis. For example, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery in resectable patients shows limited benefit, and novel treatments are urgently needed. The majority of CRC-PMs represent the CMS4 molecular subtype of CRC, and here we queried the vulnerabilities of this subtype in pharmacogenomic databases to identify novel therapies. This reveals the copper ionophore elesclomol (ES) as highly effective against CRC-PMs...
April 22, 2024: Cell reports medicine